Document is current
Any future updates will be listed below
-
Authors
Scaramuzzo, Gaetano https://orcid.org/0000-0001-9739-4082
Nucera, Francesco https://orcid.org/0000-0001-8454-5363
Asmundo, Alessio https://orcid.org/0000-0002-3159-7095
Messina, Roberto
Mari, Matilde
Montanaro, Federica https://orcid.org/0000-0003-0278-661X
Johansen, Matt D. https://orcid.org/0000-0001-5553-5270
Monaco, Francesco https://orcid.org/0000-0002-5617-7943
Fadda, Guido https://orcid.org/0000-0001-9736-0544
Tuccari, Giovanni https://orcid.org/0000-0002-1561-4246
Hansbro, Nicole G. https://orcid.org/0000-0002-2371-7990
Hansbro, Philip M. https://orcid.org/0000-0002-4741-3035
Hansel, Trevor T. https://orcid.org/0000-0003-3786-8105
Adcock, Ian M. https://orcid.org/0000-0003-2101-8843
David, Antonio https://orcid.org/0000-0003-4974-8186
Kirkham, Paul https://orcid.org/0000-0002-2575-2474
Caramori, Gaetano https://orcid.org/0000-0002-9807-327X
Volta, Carlo Alberto https://orcid.org/0000-0003-3533-6121
Spadaro, Savino https://orcid.org/0000-0001-5027-5318
- License Information
-
More Information
Article History
Received: 12 January 2023
Accepted: 8 February 2023
First Online: 20 March 2023
Declarations
:
: Not applicable.
: P.M.H. is funded by a Fellowship and grants from the National Health and Medical Research Council (NHMRC) of Australia (1175134, 2011467, 2010287), by UTS, the Rainbow Foundation and the NSW RNA Production Network. G.C.: Research grants from: Astrazeneca, Alfasigma(Biofutura has merged inside it), Boehringer Ingelheim, Chiesi Farmaceutic, Enfarma, GSJ, Menarini Group, Vivisol. Lecture fees and/or grants for travel and accommodation to participate to scientific meetings: Astrazeneca, Alfasigma(Biofutura has merged inside it), Boehringer Ingelheim, Chiesi Farmaceutic, Enfarma, GSJ, Menarini Group, Vivisol. Unrestricted educational grants from: Astrazeneca, Alfasigma(Biofutura has merged inside it), Boehringer Ingelheim, Chiesi Farmaceutic, Enfarma, GSJ, Menarini Group, Vivisol.
